Roman R. Schimmer

Roman R. Schimmer

Auto-generated profile, based on publicly available information

Roman R. Schimmer

Department of Medical Oncology and Hematology, University of Zurich and University Hospital Zurich, Zurich, Switzerland

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 February 2024 in EMBO Molecular Medicine
Verified
Journal Article
Open access
JMJan Mueller
Jan Mueller
RSRoman R Schimmer
Roman R Schimmer
CKChristian Koch
Christian Koch
FSFlorin Schneiter
Florin Schneiter
JFJonas Fullin
Jonas Fullin
SBSteffen Boettcher
Steffen Boettcher
TP53 -mutant acute myeloid leukemia (AML) and myelodysplastic neoplasms (MDS) are characterized by chemotherapy resistance and represent an unmet clinical need. Chimeric antigen receptor (CAR) T-cells might be a promising therapeutic option for TP53 -mutant AML/MDS. However, the impact of TP53 deficiency in AML cells on the efficacy of CAR T-cells is unknown. We here show that CAR T-cells engaging TP53 -deficient leukemia cells exhibit a prolonged interaction time, upregulate exhaustion markers, and are inefficient to control AML cell outgrowth in vitro and in vivo compared to TP53 wild-type cells. Transcriptional profiling revealed that the mevalonate pathway is upregulated in TP53 -deficient AML cells under CAR T-cell attack, while CAR T-cells engaging TP53 -deficient AML cells downregulate the Wnt pathway. In vitro rational targeting of either of these pathways rescues AML cell sensitivity to CAR T-cell-mediated killing. We thus demonstrate that TP53 deficiency confers resistance to CAR T-cell therapy and identify the mevalonate pathway as a therapeutic vulnerability of TP53 -deficient AML cells engaged by CAR T-cells, and the Wnt pathway as a promising CAR T-cell therapy-enhancing approach for TP53 -deficient AML/MDS.

1 July 2020 in Gastroenterology
Verified
Journal Article
Open access
PDF file
MHMarc E. Healy
Marc E. Healy
YBYannick Boege
Yannick Boege
MHMichael C. Hodder
Michael C. Hodder
FBFriederike Böhm
Friederike Böhm
MMMohsen Malehmir
Mohsen Malehmir
AWAchim Weber
Achim Weber
Background & Aims Intestinal epithelial homeostasis depends on a tightly regulated balance between intestinal epithelial cell (IEC) death and proliferation. While the disruption of several IEC death regulating factors result in intestinal inflammation, the loss of the anti-apoptotic BCL2 family members BCL2 and BCL2L1 has no effect on intestinal homeostasis in mice. We investigated the functions of the antiapoptotic protein MCL1, another member of the BCL2 family, in intestinal homeostasis in mice. Methods We generated mice with IEC-specific disruption of Mcl1 (Mcl1ΔIEC mice) or tamoxifen-inducible IEC-specific disruption of Mcl1 (i-Mcl1ΔIEC mice); these mice and mice with full-length Mcl1 (controls) were raised under normal or germ-free conditions. Mice were analyzed by endoscopy and for intestinal epithelial barrier permeability. Intestinal tissues were analyzed by histology, in situ hybridization, proliferation assays, and immunoblots. Levels of calprotectin, a marker of intestinal inflammation, were measured in intestinal tissues and feces. Results Mcl1ΔIEC mice spontaneously developed apoptotic enterocolopathy, characterized by increased IEC apoptosis, hyperproliferative crypts, epithelial barrier dysfunction, and chronic inflammation. Loss of MCL1 retained intestinal crypts in a hyperproliferated state and prevented the differentiation of intestinal stem cells. Proliferation of intestinal stem cells in MCL1-deficient mice required WNT signaling and was associated with DNA damage accumulation. By 1 year of age, Mcl1ΔIEC mice developed intestinal tumors with morphologic and genetic features of human adenomas and carcinomas. Germ-free housing of Mcl1ΔIEC mice reduced markers of microbiota-induced intestinal inflammation but not tumor development. Conclusion The antiapoptotic protein MCL1, a member of the BCL2 family, is required for maintenance of intestinal homeostasis and prevention of carcinogenesis in mice. Loss of MCL1 results in development of intestinal carcinomas, even under germ-free conditions, and therefore does not involve microbe-induced chronic inflammation. Mcl1ΔIEC mice might be used to study apoptotic enterocolopathy and inflammatory bowel diseases.

27 May 2022 in Blood Advances
Verified
Journal Article
Open access
PDF file
RSRoman R. Schimmer
Roman R. Schimmer
LKLarisa Vladimirovna Kovtonyuk
Larisa Vladimirovna Kovtonyuk
NKNancy Klemm
Nancy Klemm
JFJonas Fullin
Jonas Fullin
SSSebastian M. Stolz
Sebastian M. Stolz
SBSteffen Boettcher
Steffen Boettcher
Roman Schimmer, Larisa Vladimirovna Kovtonyuk, Nancy Klemm, Jonas Fullin, Sebastian M. Stolz, Jan Mueller, Caiado Francisco, Kari J. Kurppa, Benjamin L. Ebert,

2 January 2024 in British Journal of Haematology
Verified
Journal Article
Closed access
RSRoman R. Schimmer
Roman R. Schimmer
TSTabea Sutter
Tabea Sutter
ABAdrian Bachofner
Adrian Bachofner
ERElisabetta Ranieri
Elisabetta Ranieri
ARAnn‐Kathrin Rodewald
Ann‐Kathrin Rodewald
JSJan‐Dirk Studt
Jan‐Dirk Studt

17 December 2025 in Leukemia
Verified
Journal Article
Open access
PDF file
JFJonas Fullin
Jonas Fullin
ETEbru Topçu
Ebru Topçu
KZKarolina A. Zielińska
Karolina A. Zielińska
RSRoman R. Schimmer
Roman R. Schimmer
NKNancy Klemm
Nancy Klemm
SBSteffen Boettcher
Steffen Boettcher
Therapy-related acute myeloid leukemia and myelodysplastic neoplasms (t-AML/MDS) are devastating complications of chemo- or radiation therapy in patients treated for an unrelated primary malignancy. Cancer patients with TP53 -mutant hematopoietic stem and progenitor cells (HSPCs) – a condition termed clonal hematopoiesis (CH) – are at a particularly high risk for t-AML/MDS. However, the pathogenesis of TP53 -mutant t-AML/MDS, especially the role of the TP53 allelic state (i.e., mono- vs. biallelic), and its prognostic impact in AML/MDS have remained only poorly understood. We developed novel in vitro and in vivo mouse models to investigate how mono- or biallelic Trp53 mutations influence clonal expansion and leukemic progression from CH to t-AML/MDS. While HSPCs with monoallelic Trp53 mutations gain clonal fitness but retain their genomic integrity under chemo- or radiation therapy, biallelic Trp53 mutations result in genomic instability and are essential for leukemic transformation. Moreover, we provide proof of concept that non-mutational p53 inactivation, such as MDM2 overexpression, can replicate the effects of biallelic TP53 mutations, providing a possible explanation for cases of TP53 -mutant AML/MDS that retain one wild-type TP53 allele. Our findings elucidate the pathogenesis of TP53 -mutant t-AML/MDS and support the classification of biallelic TP53 -mutant AML/MDS as distinct clinical entities.

31 March 2025 in Cancer Research
Verified
Journal Article
Open access
NKNancy Klemm
Nancy Klemm
RSRoman R. Schimmer
Roman R. Schimmer
NKNils K. Konrad
Nils K. Konrad
FTFlavian Thelen
Flavian Thelen
JFJonas Fullin
Jonas Fullin
SBSteffen Boettcher
Steffen Boettcher
Missense mutants of p53, such as the frequent hotspot variant R248Q, exert a dominant-negative effect (DNE) on wild-type (WT) p53 in cancer cells with monoallelic TP53 mutations. However, the precise functional and molecular mechanisms of the DNE have remained elusive due to a lack of appropriate model systems. In this study, we developed a variety of model systems, including CRISPR-edited human isogenic cell lines and transcriptional reporter cell lines, and targeted protein degradation assays that were combined with functional and molecular analyses to functionally characterize the DNE. Formation of heterotetramers between R248Q and WT p53 impaired proper WT p53 functionality by preventing DNA binding and subsequent target gene transactivation. Furthermore, the markedly increased protein half-life of R248Q led to supraphysiologic levels of R248Q, which was critically required for the DNE. Drug-induced targeted protein degradation of R248Q to lower the R248Q:WT ratio restored the transcriptional activity of WT p53, induced antiproliferative effects in cancer cells in vitro, and elicited strong therapeutic activity in vivo. Together, this study provides mechanistic insights into the DNE of p53 missense mutants and indicates that the DNE represents a promising therapeutic target. Significance: Heterotetramerization between R248Q mutant and wild-type p53 in conjunction with supraphysiologic p53R248Q accumulation underlies the dominant-negative effect, highlighting the need to develop pharmacologic strategies to decrease the elevated R248Q:WT ratio. See related commentary by Gencel-Augusto and Lozano, p. 1955